Contact Lenses News and Research

RSS

Contact lenses are explicitly designed optical devices that can be worn directly on the cornea of the eye. People with poor eyesight wear contact lenses, which helps to refocus oncoming light rays on the retina to achieve a clear vision. Contact lenses increase or decrease the focusing potential of the cornea, and thereby directly project light onto the retina and aid in treating refractive errors.

Spray-on organic/inorganic films

Coatings functionalize surfaces or protect them from processes such as corrosion, abrasion, and weathering, and may provide an aesthetic appearance—automotive coatings and non-stick frying pans are good examples. Contact lenses, implants, LEDs, or photovoltaic cells require extremely thin coatings. In the journal Angewandte Chemie, the teams led by Gero Decher at the Institut Charles Sadron in Strasbourg (France) have now introduced a new process for the production of ultrathin coatings that is especially simple, versatile, and suitable for large-scale processes.

24 Nov 2010

Waterstone Group honors Coastal in Best Emerging Organization category

Coastal Contacts Inc., the leading online retailer of contact lenses and prescription eyeglasses and its Canadian subsidiary Clearly Contacts.ca, today announced that it had been selected as one of Canada's 10 Most Admired Corporate Cultures of 2010.

20 Nov 2010

AAO to recognize UH optometry dean with Charles F. Prentice Medal Award

Earl L. Smith III, O.D., dean of the College of Optometry and Greeman-Petty Professor at the University of Houston, is the 2010 recipient of the Charles F. Prentice Medal Award from the American Academy of Optometry.

19 Nov 2010

Employees will see changes in 2011 health benefits

"Workers who have received their annual enrollment packets for insurance benefits" should expect slight changes to their plans this year due to the health care overhaul. Most employees can expect to pay more next year, due in part to the 1 to 2 percent increase in insurance costs brought about by the law.

16 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

FlexBone shows potential replacement for current bone transplantations

With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.

25 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

FDA provides update on three-part study of LASIK procedure

The U.S. Food and Drug Administration today provided an update on a three-part study of LASIK (Laser-Assisted in situ Keratomileusis), a vision improvement procedure.

20 Oct 2010

Coastal Contacts receives BC Export Award

Coastal Contacts Inc., the world's largest online retailer of contact lenses and eyeglasses, was named by the Canadian Manufacturers & Exporters (CME) and the Ministry of Small Business, Technology and Economic Development to receive a BC Export Award as one of the top 25 exporters in British Columbia in 2010.

5 Oct 2010

FDA clears Abbott's RevitaLens Ocutec contact lens disinfecting solution

Abbott has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.

30 Sep 2010

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

17 Sep 2010

Coastal Contacts third-quarter sales increase 12% to record $39.5 million

Coastal Contacts Inc. today announced its financial results in Canadian dollars for the third fiscal quarter ended July 31, 2010.

13 Sep 2010

STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

STAAR Surgical Company, the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by leading ophthalmologists at meetings prior to and during the 2010 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) held in Paris, France from September 4 through 8, 2010.

8 Sep 2010

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.

8 Sep 2010

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

A new study from researchers in Canada and Sweden has shown that biosynthetic corneas can help regenerate and repair damaged eye tissue and improve vision in humans.

26 Aug 2010

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in The Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.

16 Aug 2010

August is National Immunization and Cataract Awareness Month

Childhood immunizations keep our children safe from a number of serious diseases. This is a good time of year to make sure your child is up-to-date on all of his/her immunizations. Continue reading to find out which vaccines the Centers for Disease Control and Prevention (CDC) recommend for children 6 and under.

16 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

Canadian Olympic figure skater's struggle with clear vision

Canadian figure skater, and Olympic bronze medalist Joannie Rochette - who captured the hearts of people worldwide with her stunning performance at the 2010 Vancouver Winter Olympics - is offering fans a rare glimpse into her past and her struggle with clear vision.

11 Aug 2010